Effectiveness of the immunomodulator thymalin in experimental coronavirus infection

The situation with the COVID-19 pandemic in world is still tense. Due to peculiarities of its pathogens, there a low efficiency use available specific etiotropic drugs, which leads need search for new active means combating this dangerous infectious disease. Since function T-cell immunity significantly impaired COVID-19, it advisable find out effect correcting part immune response on course coronavirus infection. For purpose, screening study was conducted determine effectiveness thymus preparation thymalin an experiment laboratory mice infected murine hepatitis virus, belongs same subgroup coronaviruses that includes SARS-CoV-2, causative agent pandemic. It found drug protected at level 45.0–60.0 % compared controls and increased average life expectancy test animals by 2.6–5.6 days control group, percentage terms 51–110 %. results obtained can serve as basis conducting regulated clinical trials aim using official medicinal product practice prevention treatment infections humans, including COVID-19.